Rhythm Pharmaceuticals, Inc.
RYTM
Rang in aandelen
#3013
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aandeelprijs
$88.37
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$6.08B
Verandering (1 dag)
2.55%
Verandering (1 jaar)
-21.37%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Categorie
Healthcare
Dividendrendementgeschiedenis voor Rhythm Pharmaceuticals, Inc. (RYTM)
Het dividendrendement (TTM) van Rhythm Pharmaceuticals, Inc. (aandelsymbool: RYTM) per 2023-12-31 is: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.02%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.02%
Dividendrendementgeschiedenis van Rhythm Pharmaceuticals, Inc. (RYTM) van 2012 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.12% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
